Wednesday, October 1, 2025

Future trends in cell and gene therapies (2026-2030): Crisis, opportunity, or both?

China-origin assets accounted for an even larger share of big pharma licensing in Q1 2026

https://www.jpmorgan.com/content/dam/jpmorgan/documents/cb/insights/outlook/jpm-biopharma-deck-q1-2026.pdf